Amgen Raises The Oncology Drug Price Bar With Blincyto
This article was originally published in The Pink Sheet Daily
Executive Summary
The first-in-class bispecific T-cell engager (BiTE) antibody will cost $178,000 for a median treatment regimen of two cycles, the company announced.